Evolution of endoscopic surgical therapy for Zenker's diverticulum
β Scribed by Alexander T. Hillel; Paul W. Flint
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 256 KB
- Volume
- 119
- Category
- Article
- ISSN
- 0023-852X
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Zenker's diverticulum is a rare anatomic defect that physicians have confronted for almost 250 years. Its location at the interface of the pharynx, neck, and mediastinum makes surgical access difficult and risks severe morbidity. Minimally invasive endoscopic surgical repair of Zenker's diverticulum has been attempted for more than a century as an alternative to reduce morbidity of an open transcervical approach. However, limitations due to available antibiotics, instrumentation, and laryngoscopes, as well as a general discomfort with a sutureless closure of the mucosal excision, have delayed widespread adoption of minimally invasive repair until the last 10 to 15 years. This manuscript will detail the historical evolution of endoscopic surgical therapy for Zenker's diverticulum and highlight the work of two otolaryngologists, Chevalier Jackson and Gosta Dohlman, who were critical in advancing the surgical technique and reducing morbidity. Lastly, this manuscript will analyze the delay in widespread application of endoscopic surgical repair of Zenker's diverticulum. Laryngoscope, 119:39β44, 2009
π SIMILAR VOLUMES
## Abstract ## Objectives/Hypothesis: This study aimed to evaluate the results of endoscopic laserβassisted diverticulotomy and the transcervical approach in treating Zenker's diverticulum. ## Study Design: Retrospective clinical study. ## Methods: Results of 155 cases after endoscopic laserβa
## Abstract ## Background. Zenker's diverticulum may be treated with a variety of surgical techniques. Endoscopic methods, specifically endoscopic stapling diverticulotomy, have gained increasing acceptance because of shorter operative times, decreased morbidity, with shorter hospital stays and ti
Diagnostic radiopharmaceuticals should reflect in vivo biochemistry. Therapeutic radiopharmaceuticals should kill tumor cells while sparing healthy cells. As the understanding of a biological process increases, synthetic chemists must be ever poised to improve the design of new radiotracers to refle